Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Chronic myeloid leukemia
Asciminib (STAMP inhibitor; ABL myristoyl-pocket) delivers rapid MR2/MR3 with low discontinuation in 1L US CML-CP RWE
Asciminib (SCEMBLIX) is a first-in-class BCR::ABL1 “STAMP” inhibitor that binds the ABL myristoyl pocket (allosteric), here used as first-line therapy for newly diagnosed Ph+ CML-CP (no T315I) in a US retrospective…
- Trial result
Kidney cancer
Chemo + checkpoint inhibitor (PD-1/PD-L1) extends OS vs chemo alone in metastatic head & neck PD-NEC (NCDB)
In this NCDB real‑world cohort (2018–2023) of metastatic poorly differentiated head and neck neuroendocrine carcinomas (HN‑NECs; n=275; survival data available for 227), systemic chemotherapy (typical backbone in…
- Trial result
Liver and bile duct cancer
Rilvegostomig (PD-1×TIGIT bispecific) + gem/cis posts 16.8-mo OS in 1L advanced BTC
Rilvegostomig (R) is a monovalent, Fc-reduced PD-1×TIGIT bispecific antibody designed to synchronously block PD-1 and TIGIT on immune effector cells; it was combined with gemcitabine/cisplatin in the global Phase 2…
NCT05775159 - Trial result
Sarcoma and GIST
Regorafenib (multi-kinase/VEGFR TKI) shows numerically longer OS in advanced sarcoma, but crossover-adjusted benefit drives the signal
Regorafenib is an oral multi-kinase inhibitor with anti-angiogenic activity (notably VEGFR) that has been studied across multiple sarcoma subtypes; this pooled OS analysis combined two randomized, double-blind,…
NCT01900743 - Trial result Spotlight
Bladder and urothelial cancer
Ave + SG (TROP2 ADC) extends PFS across visceral/liver/bone subgroups vs avelumab alone in 1L maintenance aUC
Avelumab is a PD-L1 inhibitor, and sacituzumab govitecan (SG) is a TROP2-directed ADC delivering SN-38; this randomized Phase 2 JAVELIN Bladder Medley trial (NCT05327530) tested Ave + SG vs avelumab monotherapy as 1L…
NCT05327530 - Trial result
Bladder and urothelial cancer
Zelenectide pevedotin (BT8009) Nectin-4–targeted BDC + pembrolizumab hits 50% cORR and 13.0-mo mPFS in 1L cisplatin-ineligible la/mUC
Zelenectide pevedotin (zele; BT8009) is a Nectin-4–targeted Bicycle Drug Conjugate delivering MMAE (small 4.2 kDa construct with short plasma half-life), combined here with PD-1 blockade (pembrolizumab) in Duravelo-1…
NCT04561362 - Trial result
Bladder and urothelial cancer
Avelumab (PD-L1) 1L maintenance extends OS regardless of NECTIN4/HER2 RNA in la/mUC
Avelumab is an anti–PD-L1 monoclonal antibody used as first-line (1L) maintenance after platinum-based chemotherapy (PBC) in unresectable locally advanced/metastatic urothelial carcinoma (la/mUC). In the Phase 3…
NCT02603432 - Trial result
Bladder and urothelial cancer
Durvalumab (PD-L1) + tremelimumab (CTLA-4) neoadjuvant combo hits 44% pCR—but higher CTLA-4 dose triggers serious irAEs in cisplatin-ineligible MIBC
Durvalumab (anti–PD-L1) plus tremelimumab (anti–CTLA-4) was evaluated in a pilot neoadjuvant study for cisplatin-ineligible, high-risk muscle-invasive urothelial carcinoma (NCT02812420), with cystectomy planned 4–6…
NCT02812420 - Trial result
Bladder and urothelial cancer
Zelenectide pevedotin (BT8009) Nectin‑4 BDC + pembrolizumab delivers ~55–58% ORR in 1L la/mUC (Duravelo‑2 IA)
Zelenectide pevedotin (zele; BT8009) is a Nectin‑4–targeted Bicycle Drug Conjugate (BDC) evaluated with pembrolizumab in the Phase 2/3 Duravelo‑2 trial (NCT06225596; Cohort 1, previously untreated la/mUC; randomized…
NCT06225596 - Trial result
Bladder and urothelial cancer
LY4101174 (Nectin-4–targeted exatecan ADC) shows 18% ORR post-enfortumab vedotin in mUC—but with heavy hematologic toxicity
LY4101174 is a next-generation anti–Nectin-4 antibody-drug conjugate delivering the topoisomerase I inhibitor exatecan (DAR 8; maleimide–β-glucuronide poly-sarcosine linker) being evaluated in the EXCEED Phase 1…
NCT06238479 - Trial result
Bladder and urothelial cancer
LY4052031 (Nectin-4 topo1 ADC) delivers 48% ORR in metastatic urothelial cancer, including post-enfortumab activity
LY4052031 is a next-generation anti–Nectin-4 antibody-drug conjugate (ADC) with a cleavable linker and a novel topoisomerase I inhibitor payload (Camp98; DAR 8) evaluated in the NEXUS-01 Phase 1 dose-escalation study…
NCT06465069 - Trial result Spotlight
Colorectal cancer
Ivonescimab (PD-1×VEGF bispecific) + mFOLFOX6 posts 70.8% ORR and 100% DCR in 1L unresectable mCRC (Phase 2)
Ivonescimab is an investigational tetrameric bispecific antibody co-targeting PD-1 and VEGF, here combined with oxaliplatin/5-FU/leucovorin (mFOLFOX6) as first-line therapy in a multiregional Phase 2 trial…
NCT05382442 - Trial result Spotlight
Colorectal cancer
Zongertinib (selective irreversible HER2 TKI) drives 45% ORR with mostly grade 1 diarrhea in HER2+ CRC
Zongertinib is an irreversible, HER2-selective tyrosine kinase inhibitor designed to spare wild-type EGFR (aiming to reduce classic EGFR-TKI rash/diarrhea) and was evaluated as monotherapy in a pooled subgroup of…
NCT04886804 - Trial result
Colorectal cancer
ABFOLFOX (PD-L1 + VEGF + FOLFOX) drives immune-activated CRLM states, with 35% durable control
Atezolizumab (anti–PD-L1) + bevacizumab (anti-VEGF) + leucovorin/5-FU/oxaliplatin (FOLFOX) was evaluated as neoadjuvant therapy for unresectable colorectal liver metastases (CRLM) in a prospectively registered cohort…
NCT03698461 - Trial result
Colorectal cancer
Ozekibart (INBRX-109) DR5 agonist + FOLFIRI delivers 23% ORR in 4L+ metastatic CRC
Ozekibart (INBRX-109) is a next-generation tetravalent death receptor 5 (DR5) agonist designed to induce tumor cell apoptosis; here it was combined with FOLFIRI in an open-label Phase 1 expansion cohort (C4d;…
NCT03715933 - Trial result
Colorectal cancer
Ad5.F35-GUCY2C-PADRE (GUCY2C-directed adenoviral vaccine) drives dose-dependent T-cell immunity and signals improved 2-year RFS in resected CRC
Ad5.F35-GUCY2C-PADRE is an off-the-shelf chimeric Ad5/35 vector vaccine targeting the intestinal tumor antigen GUCY2C and incorporating PADRE to enhance CD4+ help, designed to bypass pre-existing anti-Ad5…
NCT04111172 - Trial result
Colorectal cancer
Sotorasib (KRAS G12C inhibitor) + panitumumab (EGFR mAb) links early ctDNA clearance to longer survival in chemorefractory mCRC
Sotorasib is an oral covalent KRAS G12C inhibitor, and panitumumab is an anti-EGFR monoclonal antibody; in the Phase 3 CodeBreaK 300 trial (NCT05198934) in chemorefractory KRAS G12C–mutant mCRC, this analysis tested…
NCT05198934 - Trial result
Colorectal cancer
ST316 β-Catenin/BCL9 Antagonist Reaches 46.7% ORR With 2L FOLFIRI/Bev in MSS mCRC
ST316 is a first-in-class IV peptide antagonist of the β-catenin–BCL9/9L interaction, designed to suppress oncogenic Wnt/β-catenin transcription while sparing physiologic Wnt signaling. In the ongoing Phase 1/2…
NCT05848739 - Trial result
Colorectal cancer
Telisotuzumab adizutecan (Temab-A; ABBV-400) c-Met–targeted topo-1 ADC posts 37% ORR in platinum-resistant ovarian cancer
Telisotuzumab adizutecan (Temab-A; ABBV-400) is a c-Met protein–targeting antibody–drug conjugate delivering a topoisomerase 1 inhibitor payload; in this Phase 1 open-label basket cohort (NCT06084481), patients with…
NCT06084481 - Trial result
Colorectal cancer
Leronlimab (CCR5 mAb) + TAS-102/Bev shows early ctDNA drops and 100% stable disease in refractory mCRC (CLOVER)
Leronlimab (LRM) is a subcutaneous anti-CCR5 humanized monoclonal antibody being added to the current late-line standard regimen trifluridine/tipiracil (TAS-102) plus bevacizumab in the open-label Phase 2 CLOVER…
NCT06699836 - Trial result Spotlight
Multiple solid tumors
Olverembatinib (HQP1351) hits p38–CD36 lipid-scavenging axis, delivers 23% PR and 25.7-mo PFS in SDH-deficient GIST
Olverembatinib (HQP1351) is an oral multikinase TKI with p38 inhibition implicated here in downregulating CD36 (fatty-acid uptake), a metabolic vulnerability in SDH-deficient tumors. In the HQP1351SJ0003 Phase 1b…
NCT03594422 - Trial result Spotlight
Multiple solid tumors
NT-175 (TP53 R175H–HLA-A*02:01 eTCR; TGFβR2-knockout) drives 47.6% ORR across refractory solid tumors (83% PR in PDAC)
NT-175 is an autologous CRISPR/Cas9-edited engineered TCR T-cell therapy targeting the TP53 R175H neoantigen in an HLA-A*02:01-restricted manner, with endogenous TGFβR2 deleted (to reduce TGF-β–mediated suppression)…
NCT05877599 - Trial result Spotlight
Multiple solid tumors
HCB101 (SIRPα–IgG4 Fc; CD47 checkpoint blocker) shows early monotherapy PRs and high combo disease control in gastric cancer
HCB101 is a CD47–SIRPα axis inhibitor (engineered SIRPα–IgG4 Fc fusion) designed to preserve pro-phagocytic macrophage activity while minimizing red-blood-cell binding/hematologic toxicity. In the first-in-human…
NCT05892718 - Trial result Spotlight
Multiple solid tumors
Darlifarnib (KO-2806) FTI (RHEB/mTORC1) + adagrasib drives 67% ORR in KRAS G12C NSCLC (Ph1 FIT-001)
Darlifarnib (KO-2806) is a next-generation farnesyl transferase inhibitor designed to block farnesylation-dependent RHEB signaling and dampen mTORC1 activity (a proposed resistance node to KRAS G12C inhibition); in…
NCT06026410 - Trial result Spotlight
Multiple solid tumors
SIM0505 (anti-CDH6 topo-I ADC) drives 37% PRs in heavily pretreated gynecologic tumors
SIM0505 is a first-in-class cadherin-6 (CDH6)–targeted antibody–drug conjugate delivering the novel topoisomerase I payload CPT116; it was evaluated in a global Phase I first-in-human dose-escalation study in…
NCT06792552 - Trial result Spotlight
Multiple solid tumors
TILScore-Guided TIL Therapy Produces 33% ORR in Checkpoint-Refractory Solid Tumors
TILScore is an in situ transcriptomic biomarker used to select a metastasis for autologous TIL harvest and “reactive-enriched” manufacturing before lymphodepletion, TIL infusion, and high-dose IL-2. In a…
NCT03935893 - Trial result
Multiple solid tumors
Larotrectinib (TRK inhibitor) delivers 65% ORR and 42-mo DoR in non-primary CNS NTRK fusion cancers
Larotrectinib (laro) is a first-in-class, highly selective TRKA/B/C (NTRK1/2/3) inhibitor evaluated in an updated pooled analysis of 3 trials (SCOUT/NAVIGATE/LOXO-TRK-14001; data cutoff July 20, 2025) in adult and…
- Trial result
Multiple solid tumors
Mecbotamab vedotin (CAB-AXL-ADC) delivers 17.6-mo median OS in heavily pretreated bone sarcomas
Mecbotamab vedotin (Mec‑V; BA3011) is a low-pH conditionally binding AXL-targeted antibody–drug conjugate (ADC) designed to preferentially engage AXL in the acidic tumor microenvironment and limit off-tumor toxicity.…
NCT03425279 - Trial result
Multiple solid tumors
Belzutifan (HIF-2α inhibitor) Delivers 6-Year, Surgery-Sparing Control in VHL RCC/CNS HB/pNET
Belzutifan is an oral, potent hypoxia-inducible factor 2α (HIF-2α) inhibitor evaluated in the open-label, single-arm Phase 2 LITESPARK-004 study (NCT03401788) for germline VHL patients with nonmetastatic RCC not…
NCT03401788 - Trial result
Multiple solid tumors
Stop vs continue PD-1/PD-L1 at 1 year shows similar “cure” and PFS, with OS signal favoring stopping
In the randomized Phase 3 NCT04157985 trial, patients with advanced solid tumors who had ≥SD after 1 year of standard-of-care PD-1/PD-L1 inhibitor therapy were randomized to stop vs continue immunotherapy (n=161;…
NCT04157985
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.